Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
44 hedge funds and large institutions have $162M invested in Mirati Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 8 closing their positions.
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
33% more funds holding
Funds holding: 33 → 44 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $172M → $162M (-$9.87M)
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.41M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$2.77M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.13M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.11M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.25M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.85M |
| 4 |
O
OrbiMed
New York
|
-$1.98M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.44M |
MRTX Hedge Fund Activity: Q2 2014 in Review
44 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2014, worth a combined $162M — down 5.7% from $172M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MRTX positions and 8 closed out — a net gain of 11 holders — while 6 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $3.41M. The largest seller was RA Capital Management, exiting entirely with an estimated $12.5M sold.
- 44 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2014, up from 33 in Q1 2014.
- Funds reported $162M of Mirati Therapeutics, Inc. Common Stock stock for Q2 2014, down 5.7% quarter-over-quarter.
- 19 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2014 and 8 closed out, a net change of +11 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $3.41M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2014 was RA Capital Management, an estimated $12.5M sold.
Based on aggregated 13F filings for Q2 2014.